Harrow (NASDAQ:HROW) PT Raised to $45.00

Harrow (NASDAQ:HROW) had its price objective increased by stock analysts at Craig Hallum from $30.00 to $45.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s target price points to a potential upside of 25.21% from the company’s current price.

A number of other equities research analysts also recently issued reports on the company. Lake Street Capital boosted their price target on Harrow from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, June 3rd. B. Riley lifted their price objective on Harrow from $29.00 to $50.00 and gave the company a “buy” rating in a research note on Friday.

Harrow Trading Up 6.0 %

Harrow stock traded up $2.02 during trading on Friday, hitting $35.94. The company’s stock had a trading volume of 1,565,346 shares, compared to its average volume of 482,228. The stock’s fifty day moving average is $22.16 and its 200 day moving average is $15.57. Harrow has a 1-year low of $7.60 and a 1-year high of $36.00. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -39.49 and a beta of 0.77. The company has a debt-to-equity ratio of 3.06, a quick ratio of 2.75 and a current ratio of 3.00.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.03). The business had revenue of $34.59 million during the quarter, compared to analysts’ expectations of $34.37 million. Harrow had a negative net margin of 22.59% and a negative return on equity of 39.82%. As a group, equities research analysts predict that Harrow will post -0.51 EPS for the current year.

Institutional Trading of Harrow

A number of institutional investors have recently added to or reduced their stakes in HROW. Rice Hall James & Associates LLC raised its position in Harrow by 4.4% in the second quarter. Rice Hall James & Associates LLC now owns 255,862 shares of the company’s stock valued at $5,345,000 after purchasing an additional 10,761 shares during the period. Los Angeles Capital Management LLC purchased a new position in Harrow in the second quarter valued at about $1,698,000. BBR Partners LLC boosted its holdings in Harrow by 120.0% in the second quarter. BBR Partners LLC now owns 22,000 shares of the company’s stock valued at $460,000 after purchasing an additional 12,000 shares during the last quarter. Rhumbline Advisers grew its stake in Harrow by 8.2% during the 2nd quarter. Rhumbline Advisers now owns 43,021 shares of the company’s stock valued at $899,000 after purchasing an additional 3,253 shares in the last quarter. Finally, Drive Wealth Management LLC increased its holdings in Harrow by 63.1% during the 2nd quarter. Drive Wealth Management LLC now owns 29,551 shares of the company’s stock worth $617,000 after purchasing an additional 11,434 shares during the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.